UroGen Pharma Ltd. (URGN) stock
Close on Nov 13, 2026Market cap $1.28BP/E –Yield –
UroGen Pharma Ltd. grew revenue 159.3% to $250.25M over the twelve months to Sep 30, 2026. Free cash flow was -$132.05M. At the latest close the market valued the company at $1.28B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.28B
- P/E ratio
- –
- Price to sales
- 5.11
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -10.32%
Fundamentals
- Revenue
- $250.25M
- Net income
- -$65.75M
- EPS, diluted
- -$1.32
- Free cash flow
- -$132.05M
- Book value per share
- -$2.48
- Diluted shares
- 51M
Trading
- Next earnings
- Mar 1, 2027 (estimated, before the open)
- Previous close
- $26.39
- Open
- $26.65
- Day's range
- $25.25 – $26.65
- Volume
- 700,015
- Average volume (20 days)
- 1,262,765
- Beta (5 years)
- 0.87
- 52-week range
- $16.50 – $50.81
- RSI (14 days)
- 28.7
- Volatility (1 year)
- 62.0%
- Relative volume
- 0.72×
- WACC
- 8.9%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | URGN | S&P 500 | Difference | URGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -31.6% | -3.0% | −28.5 pts | ||
| 3 months | -45.6% | -2.8% | −42.8 pts | ||
| Year to date | +11.8% | +11.5% | +0.3 pts | ||
| 1 year | +9.4% | +13.5% | −4.0 pts | ||
| 3 years | +122.6% | +77.7% | +44.9 pts | +30.6% | +21.1% |
| 5 years | +36.9% | +72.6% | −35.8 pts | +6.5% | +11.5% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases UroGen Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About UroGen Pharma
Pharmaceutical Preparations
UroGen Pharma is a biotechnology company focused on developing and commercializing therapeutic solutions for urothelial and specialty cancers. Utilizing its proprietary reverse-thermal hydrogel technology, RTGel, the company creates sustained-release formulations designed to extend drug exposure in the urinary tract. Its approved commercial products include Jelmyto, developed to ablate tumors non-surgically in adult patients with low-grade upper tract urothelial cancer, and Zusduri, designed for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Additionally, the company advances pipeline candidates such as UGN-103, UGN-104, and UGN-501. Its customer base comprises healthcare professionals, physicians, hospitals, and pharmacies treating cancer patients.
Company profile, executives and historyUroGen Pharma stock: common questions
What is UroGen Pharma's stock price?
URGN closed at $26.18 on Nov 13, 2026, down 0.80% on the day. Over the past 52 weeks it traded between $16.50 and $50.81.
What is UroGen Pharma's market cap?
UroGen Pharma was worth $1.28B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is URGN's P/E ratio?
UroGen Pharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.32), so it has no meaningful P/E ratio.
How much revenue does UroGen Pharma make?
UroGen Pharma reported revenue of $250.25M for the twelve months to Sep 30, 2026, up 159.3% from a year earlier.
Does UroGen Pharma pay a dividend?
No. UroGen Pharma has not paid a cash dividend over the last twelve months.
When does UroGen Pharma report earnings next?
UroGen Pharma is expected to report Q4 FY2026 results on Mar 1, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has URGN stock performed over the past year?
Including dividends, URGN returned +9.4% over the past year, against +13.5% for the S&P 500.
How many URGN shares are sold short?
5M shares were sold short at the latest FINRA report, 11.06% of the float, or 5.1 days of average trading volume.
Who are UroGen Pharma's competitors?
Companies most similar to UroGen Pharma by business, industry and size include RIGL, PBYI, NUVB, HRTX, PGEN.
See a number that looks wrong?